Recruiting
Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse
NCT07871864· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source
Contact: Tuuli Pöyhönen
Recruiting
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
NCT07564141· Phase 3· Genmab· Source
Recruiting
Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)
2023-505575-69-01· Phase 3· Institut Gustave Roussy· Source
Recruiting
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654· Phase 3· Boehringer Ingelheim· Source
Recruiting
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517· Phase 3· Boehringer Ingelheim· Source
Recruiting
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( RAINFOL-03 )
2024-519818-31-01· Phase 3· Genmab A/S· Source
Recruiting
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
NCT07225270· Phase 3· Genmab· Source
Recruiting
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
NCT07223814· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Recruiting
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
NCT06340568· Phase 3· BioNTech SE· Source
Recruiting
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
NCT06697301· Phase 2/3· Eikon Therapeutics· Source
Recruiting
PCA-oxycodone after cardiac surgery; respiratory effects, and short and long term outcome
2024-515530-33-00· Phase 4· Pohjois-Savon hyvinvointialue· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556· Phase 3· Hoffmann-La Roche· Source
Enrolling by invitation
Long-term Safety and Tolerability of BHV-7000
NCT06443463· Phase 2· Biohaven Therapeutics Ltd.· Source
Active, not recruiting
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06309966· Phase 2/3· Biohaven Therapeutics Ltd.· Source
Recruiting
First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT06217822· Phase 1· Bayer· Source
Recruiting
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06161025· Phase 2/3· Daiichi Sankyo· Source
Recruiting
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
NCT06262438· Phase 2· Princess Maxima Center for Pediatric Oncology· Source
Active, not recruiting
A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT06052306· Phase 1· Bayer· Source
Recruiting
CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML)
2023-504999-25-00· Phase 3· Prinses Maxima Centrum voor Kinderoncologie B.V.· Source
Recruiting
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
NCT05476939· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source
Recruiting
SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years.
2024-510578-25-00· Phase 3· The University Of Birmingham· Source
Recruiting
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
NCT04625907· Phase 1/2· University of Birmingham· Source
Recruiting
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
NCT04307576· Phase 3· Mats Heyman· Source
Recruiting
International study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine
2022-501454-11-00· Phase 3· GPOH gGmbH· Source
Recruiting
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
NCT04043494· Phase 3· University Hospital Muenster· Source
Active, not recruiting
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
NCT03981796· Phase 3· Tesaro, Inc.· Source
Active, not recruiting
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT03007147· Phase 3· Children's Oncology Group· Source
Recruiting
SIOP Ependymoma II: An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependymoma
NCT02265770· Phase 2/3· Centre Leon Berard· Source
Active, not recruiting
International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma
NCT02066220· Phase 2/3· Universitätsklinikum Hamburg-Eppendorf· Source
Recruiting
NOPHO-DBH AML 2012 Protocol: Research study for treatment of children and adolescents with acute myeloid leukemia 0-18 years
NCT01828489· Phase 3· Vaestra Goetalandsregionen· Source